This site contains promotional information intended only for healthcare professionals resident in the United Kingdom

Visit Pfizer Medical site

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLinked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkEN - EnglishSelect a languageLanguagesEN - EnglishFR - Françias

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLinked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkEN - EnglishSelect a languageLanguagesEN - EnglishFR - FrançiasSearch

Menu

Close

Sign In or RegisterLog Out
Pfizer MedicinesTherapy AreasExplore ContentEventsVideosMaterialsFeatured ArticlesLet’s ConnectSupplyAlliance HealthcareOff-contract claims

Menu

Close

EfficacyEfficacyEfficacyKey HighlightsSafetySafetySafetySelected Adverse EventsDosingDosingDosingAdditional Administration informationSupport & resourcesSupport & resourcesResource overviewPatient SupportGuidelinesELN 2022 GuidelinesKey topics in AML video seriesEfficacy and Safety videoPubExplainer videos

The content of this website has been produced in line with the MYLOTARG®▼ (gemtuzumab ozogamicin) Summary of Product Characteristics for Great Britain and Northern Ireland. For  MYLOTARG®▼ (gemtuzumab ozogamicin) and cytarabine Prescribing Information Click here. Adverse event reporting information can be found at the bottom of the page.

Additional Administration Information
  • MYLOTARG must not be used during pregnancy unless the potential benefit to the mother outweighs the potential risks to the foetus. Women or partners of women with childbearing potential should use two methods of contraception during treatment and for at least 7 months (females) or 4 months (males) after the last dose
  • Female patients should avoid breast feeding while receiving MYLOTARG and for ≥ 1 month after the final dose
  • Before administering each dose of MYLOTARG, complete blood counts should be assessed, as well as baseline liver function tests (ALT, AST, total bilirubin and ALP levels) to monitor for hepatotoxicity, including VOD
  • Premedication with a corticosteroid, antihistamine and paracetamol is recommended 1 hour prior to MYLOTARG dosing to ameliorate infusion-related reactions
  • MYLOTARG is light sensitive and should be protected from UV light during reconstitution, dilution and administration
  • Following reconstitution and dilution, MYLOTARG should be administered by IV infusion over a 2-hour period and should not be administered as an IV push or bolus
  • Infusion of MYLOTARG should be performed under close clinical monitoring, including pulse rate, blood pressure and temperature
  • Patients receiving MYLOTARG should be monitored for clinical signs and symptoms of infection, bleeding/haemorrhage, or other effects of myelosuppression and tumour lysis syndrome. Additionally, due to the risk of VOD/SOS, signs and symptoms of VOD/SOS should be closely monitored; these may include elevations in ALT, AST, total bilirubin, and alkaline phosphatase, which should be monitored prior to each dose of MYLOTARG, hepatomegaly (which may be painful), rapid weight gain, and ascites. Monitoring only total bilirubin may not identify all patients at risk of VOD/SOS. For patients who develop abnormal liver tests, more frequent monitoring of liver tests and clinical signs and symptoms of hepatotoxicity is recommended
  • Once cytogenetic testing results are available, consider the risk-benefit of continuing treatment with MYLOTARG; the efficacy of MYLOTARG has been demonstrated in AML patients with favourable- and intermediate-risk cytogenetics, but not in patients with adverse cytogenetics
 Please refer to the MYLOTARG Summary of Product Characteristics for full details Loading Pharmacy Guide

Download the Pharmacy booklet which is a guide to treatment with MYLOTARG. SmPC should be consulted for full guidance.

 Download Pharmacy Guide Loading Fast Facts Download the fast facts PDF document to aid your understanding of MYLOTARG View Fast Facts PDF Loading

ALP, alkaline phosphatase; ALT, alanine aminotransferase; AML, acute myeloid leukaemia; ANC, absolute neutrophil count; AST, aspartate aminotransferase;  IV, intravenous; SmPC, Summary of Product Characteristics; SOS, Sinusoidal Obstruction Syndrome; UV, ultraviolet; VOD, veno-occlusive disease.

Reference:MYLOTARG Summary of Product Characteristics for Great Britain click here. MYLOTARG Summary of Product Characteristics for Northern Ireland click here.
PP-MYL-GBR-0686. April 2023
 For further details on dosing and schedule Dosing Guide Loading

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search 

for MHRA Yellow Card in Google Play or Apple App Store

 

Adverse events should also be reported to Pfizer Medical Information on 01304 616161

PfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign In or RegisterAccountSign Out

This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc

 

This website is brought to you by Pfizer Limited, a company registered in England 

and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ

 

Copyright © 2023 Pfizer Limited. All rights reserved.

 

VAT registration number GB201048427

PP-UNP-GBR-4885. May 2023
For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-3863. November 2021

YesNo
You are now leaving PfizerPro​​​​​
​
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned or controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site.​​​​​​​​​​​​​​

​​​​​​​PP-PFE-GBR-3858. November 2021​​​​​​​
​​​​​​​
You are now leaving PfizerPro
​​​​​​​
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site other than the information or other materials relating to ​​​​​Pfizer medicines or 
business which it has provided or reviewed.

PP-PFE-GBR-3859. November 2021
​​​​​​​